Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 16/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 16/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901901 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4HCRTR1HCRTR2CASP3 | |
| SCHEMBL29575786 | 0.84 | ITGB1 (0.65) | ITGB1ITGA4HCRTR1HCRTR2ITGB7 | |
| SCHEMBL3904073 | 0.83 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3904078 | 0.83 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL7967513 | 0.82 | ITGB1 (0.81) | ITGB1ITGA4HCRTR1HCRTR2ITGB7 | |
| SCHEMBL6404199 | 0.81 | ITGB1 (0.51) | ITGB1ITGA4HCRTR1HCRTR2ITGB7 | |
| SCHEMBL4609883 | 0.81 | ACLY (0.55) | HCRTR1HCRTR2CASP3 | |
| SCHEMBL3904609 | 0.81 | MMP2 (0.64) | CASP3 | |
| SCHEMBL695760 | 0.81 | MMP2 (0.64) | CASP3 | |
| SCHEMBL14905820 | 0.80 | CASP3 (0.59) | HCRTR1HCRTR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2023250339-A2 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-1778717-A4 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1778717-A2 | CELL ADHESION INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7196112-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070066533-A1 | Cell adhesion inhibitors | LEE WEN-CHERNG | 2007-03-22 | — | — | US | disclosed |
| EP-1265606-B9 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1741428-A2 | Cell adhesion inhibitors | Biogen Idec MA, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1265606-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060166961-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6586602-B2 | CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-07-01 | — | — | US | disclosed |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| EP-1265606-A4 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265606-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 2002-12-18 | — | — | EP | disclosed |
| CN-1377268-A | Cell adhesion inhibitors | BIOGEN INC (US) | 2002-10-30 | — | — | CN | disclosed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | disclosed |
| WO-2001012186-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1001975-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066533-A1 | Cell adhesion inhibitors | VCAM1, EPCAM, ICAM1 | ITGB1 14/4885ITGA4 8/4885HCRTR1 4826/4885 |
| US-20060166961-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | ITGB1 6/4885ITGA4 10/4885HCRTR1 4267/4885 |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB1 35/4885ITGA4 10/4885HCRTR1 4265/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | ITGB1 27/4885ITGA4 5/4885HCRTR1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.